Your Health, We Care
Release date: 2026-01-13 17:11:45 Recommended: 156
Drugs used to treat cancer are usually highly potent and may cause numerous side effects. Before using this medication, ensure that you understand all its risks and benefits. It is extremely important to cooperate closely with your doctor during the course of treatment.
1. Take this medication strictly in accordance with your doctor’s instructions. Do not take a dose higher than prescribed, do not take it more frequently, and do not continue taking it beyond the duration specified by your doctor.
2. This medication is accompanied by a patient information leaflet. Please read it carefully and follow the instructions. If you have any questions, consult your doctor.
3. Take this medication at approximately the same time every day, either with food or on an empty stomach.
4. Swallow the tablets whole. Do not chew, crush, or split the tablets. Do not take any tablet that is broken, cracked, or damaged.
5. During treatment with this medication, do not consume grapefruit or drink grapefruit juice.
6. For women who have not yet entered menopause or have just started menopause, your doctor may also prescribe a luteinizing hormone-releasing hormone (LHRH) medication for concurrent use.
Based on animal study results and its mechanism of action, this drug may cause harm to the fetus.
Severe hyperglycemia associated with ketoacidosis has been reported in clinical trials.
The safety of this drug in patients with type 1 diabetes or those requiring insulin has not been established; insulin-dependent diabetic patients were excluded from clinical trials.
Assess fasting blood glucose levels before the initiation of treatment and during the treatment period.
If hyperglycemia develops after treatment initiation, monitor fasting blood glucose levels based on clinical indications, and conduct monitoring at least twice a week until fasting blood glucose returns to the normal range.
If a patient develops hyperglycemia during treatment, refer to the dose adjustment guidelines.
Severe diarrhea accompanied by dehydration may occur.
Monitor for signs and symptoms of diarrhea.
Patients are advised to increase oral fluid intake and initiate antidiarrheal treatment at the first sign of diarrhea during Capivasertib therapy.
Cutaneous adverse reactions may occur, which can be severe, including erythema multiforme, palmar-plantar erythrodysesthesia syndrome, and drug reaction with eosinophilia and systemic symptoms (DRESS).
Monitor for signs and symptoms of cutaneous reactions.
1. Strong CYP3A Inhibitors: Avoid concomitant use. If coadministration is unavoidable, reduce the dose of capivasertib and monitor for adverse reactions. Strong CYP3A inhibitors can increase capivasertib exposure.
2. Moderate CYP3A Inhibitors: Adjust the dose. Moderate CYP3A inhibitors can increase capivasertib exposure; if coadministration is necessary, reduce the dose of capivasertib.
3. Strong or Moderate CYP3A Inducers: Avoid concomitant use. Strong or moderate CYP3A inducers can decrease capivasertib exposure, which may reduce its therapeutic efficacy.
